New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
08:08 EDTINFIInfinity Pharmaceuticals sees FY12 revenue $47.1M, consensus $113.91M
Infinity expects FY12 total revenue $47.1M composed of $45.0M for reimbursed R&D services from Mundipharma and $2.1M due to the amortization of deferred revenue. Infinity does not expect to recognize any revenue in future periods from the previous strategic alliance with Purdue and Mundipharma. Infinity expects FY12 operating expenses $125M-$135M revised from an earlier expectation of $135M-$145M. Infinity expects FY12 net loss $35M-$45M. Cash and investments: Infinity expects to end 2012 with a year-end cash and investments balance ranging from $155M-$165M, revised from an earlier expectation of $65M-$75M.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 16, 2014
07:41 EDTINFIInfinity reports duvelisib Phase 2a primary endpoint not met
Infinity Pharmaceuticals announced encouraging topline data from its Phase 2a exploratory study of duvelisib, or IPI-145. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV1 among patients who received duvelisib administered at the highest dose tested, 25 mg twice daily for five days, however the primary endpoint of the study was not met as it did not reach statistical significance. Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.
October 13, 2014
13:05 EDTINFIInfinity Pharmaceuticals management to meet with ISI Group
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use